{"filing":{"accession_number":"0001171843-26-006065","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-09-16","report_date":"2026-09-16","primary_document":"f6k_091626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326006065/f6k_091626.htm"},"events":[{"id":33787,"run_id":31088,"accession_number":"0001171843-26-006065","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Optimi announces plans to initiate a Health Canada-authorized Phase 3 clinical trial for MDMA-assisted therapy in PTSD, expected to begin in 2027 with enrollment of up to 100 participants. This represents a material advancement of the company's clinical pipeline and regulatory strategy in psychedelic-assisted therapies, directly supporting the company's stated goal of submitting both MDMA and psilocybin products for registration. While not a discrete M\u0026A event, covenant breach, or financial transaction, this clinical milestone is operationally significant to a pharmaceutical manufacturer's value proposition and would affect a reasonable investor's assessment of the company's progress toward commercialization.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-16","form":"6-K","submitted_at":null,"items":[{"id":37316,"accession_number":"0001171843-26-006065","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Optimi announces plans to initiate a Health Canada-authorized Phase 3 clinical trial for MDMA-assisted therapy in PTSD, expected to begin in 2027 with enrollment of up to 100 participants. This represents a material advancement of the company's clinical pipeline and regulatory strategy in psychedelic-assisted therapies, directly supporting the company's stated goal of submitting both MDMA and psilocybin products for registration. While not a discrete M\u0026A event, covenant breach, or financial transaction, this clinical milestone is operationally significant to a pharmaceutical manufacturer's value proposition and would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-16T12:25:46.578456+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37316,"accession_number":"0001171843-26-006065","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Optimi announces plans to initiate a Health Canada-authorized Phase 3 clinical trial for MDMA-assisted therapy in PTSD, expected to begin in 2027 with enrollment of up to 100 participants. This represents a material advancement of the company's clinical pipeline and regulatory strategy in psychedelic-assisted therapies, directly supporting the company's stated goal of submitting both MDMA and psilocybin products for registration. While not a discrete M\u0026A event, covenant breach, or financial transaction, this clinical milestone is operationally significant to a pharmaceutical manufacturer's value proposition and would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-16T12:25:46.578456+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-16"}]}